Study on Time Course of PIVKA-II and AFP levels after hepatic artery embolization for hepatocellular carcinomas. Relation between time course in PIVKA-II and AFP levels and tumor necrosis.

Kishi, K; Sonomura, Tetsuo; Mitsuzane, K; Sato, Morio; Yamada, Ryusaku

doi:10.2957/kanzo.33.692

Cited by 10 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High DCP levels have been considered a strong predictor of recurrence in patients treated with liver resection , ablation therapy , or transarterial chemoembolization . Reports of a correlation between DCP levels and the incidence of microvascular invasion or poor differentiation support these clinical observations.…”

Section: Discussionmentioning

confidence: 93%

Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma

et al. 2014

View full text Add to dashboard Cite

SummaryTumor markers [alpha-fetoprotein (AFP) or des-gamma-carboxyprothrombin (DCP)] and neutrophil/lymphocyte ratio (NLR) reportedly correlate with longterm outcomes for hepatocellular carcinoma (HCC). However, no standardized method has been established for evaluating the pretransplant data. One hundred and twenty-four patients who underwent living donor liver transplantation (LDLT) were retrospectively reviewed. The best predictive parameters for tumor recurrence were maximum values for AFP or DCP and 90-day mean values for NLR, respectively, and multivariate analysis confirmed these values were correlated with tumor recurrence. However, receiver operating characteristic analysis revealed that discriminative powers were sufficient only in maximum AFP [area under the curve (AUC) 0.88, P < 0.001] and maximum DCP (AUC 0.76, P < 0.001), while mean NLR was less predictive (AUC 0.62, P = 0.20). When incorporating AFP and DCP to the Tokyo criteria (≤5 tumors with each tumor ≤5 cm), the presence of at least two of the following factors: (i) beyond the Tokyo criteria, (ii) AFP>250 ng/ml, and (iii) DCP > 450 mAu/ml (>450 ng/ml), was correlated with a worse 5-year disease-free survival rate (20.0% vs. 96.8%, P < 0.001) and 5-year overall survival rate (20.0% vs. 84.0%, P < 0.001). The prognosis of patients undergoing LDLT for HCC strongly relies on maximum AFP or DCP values before transplantation, while the prognostic impact of NLR is limited.

show abstract

Section: Discussionmentioning

confidence: 93%

Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma

et al. 2014

View full text Add to dashboard Cite

show abstract

“…(23)(24)(25)29) In the present study, changes of both AFP and PIVKA-II levels were focused to evaluate effectiveness of any treatments because half-life of these serum markers was limited within a few weeks. (16) We hypothesize that L group showed the lowest malignancies in all groups before treatments and, in the N group, the tumor was mostly disappeared by the effective treatments. In the ANU group, viable or active HCC might remain and HCC of ANU group might be remained and had the most aggressive malignancies in the showed that AFP L3 fraction is a better specific marker for HCC than AFP level.…”

Section: Discussionmentioning

confidence: 99%

“…As described above, changes in sensitive markers may indicate eradication of HCC. In patients with high levels of tumor markers, complete resection Nanashima et al, Page 5 or necrosis of HCC should result in normalization of tumor markers within the half life of these markers, only a couple of days (14,16). A few reports, including our preliminary studies, indicated that changes of serum levels of AFP and PIVKA-II correlate with prognosis (14,17,18).…”

Section: Introductionmentioning

confidence: 99%

Tumor Marker Levels Before and After Curative Treatment of Hepatocellular Carcinoma as Predictors of Patient Survival

et al. 2011

View full text Add to dashboard Cite

Abstract-fetoprotein (AFP) is used as a marker for hepatocellular carcinoma (HCC), which is influenced by hepatitis. Protein induced vitamin K absence or antagonist II (PIVKA-II) is a sensitive diagnostic marker. Changes in these markers after treatment may reflect curability and predict outcome. We conducted an analysis of prognosis in 470 HCC patients who received curative treatments, and examined relationship between changes in AFP and PIVKA-II levels after 1-month of treatment in 156 patients. Subjects were divided into three groups according to changes in both levels: 1) normal (L) group before treatment, 2) normalization (N) or 3) decreased but still above normal level or unchanged (ANU) group after treatment. High AFP and PIVKA-II levels were significantly associated with poor tumor-free and overall survival. Presence of large size and advanced stage were significantly associated with prevalence of DU group. Overall survival in the AFP-L group was significantly better than those of other groups and overall survival in PIVKA-II-L and N groups were significantly better than those of PIVKA-II-ANU groups. Combination of changes in AFP-ANU and PIVKA-II-ANU group showed the worst tumor-free and overall survivals. Multivariate analysis identified high pre-treatment levels of AFP and PIVKA-II and combination of AFP-ANU and PIVKA-II-ANU as significant determinants of poor tumor-free and overall survival, particularly in patients who underwent hepatectomy. We conclude that high levels of AFP or PIVKA-II after treatment for HCC did not sufficiently reflect curative efficacy of treatment and reflected a poor predictor of prognosis in HCC patients. Nanashima et al., Page 3

show abstract

“…Indeed, previous studies have demonstrated that a high DCP level at the time of HCC diagnosis is associated with poor prognosis (5,(10)(11)(12). Moreover, the high DCP levels have been considered as a predictor of recurrence in patients treated with conventional treatments such as surgical resection (9,10,13,14), transcatheter arterial embolization (TAE) (15,16) and percutaneous ablation therapy (17,18). (19) for HCC based on tumor number and size (20)(21)(22)(23)(24)(25).…”

Section: Several Groups Have Recently Reported Correlations Between Dmentioning

confidence: 99%

Significance of Des-Gamma-Carboxy Prothrombin in Selection Criteria for Living Donor Liver Transplantation for Hepatocellular Carcinoma

Fujiki

Takada

Ogura

et al. 2009

American Journal of Transplantation

163

198

View full text Add to dashboard Cite

Des-gamma-carboxy prothrombin (DCP) levels reportedly correlate with histological features of hepatocellular carcinoma (HCC). We examined serum DCP as a predictor of HCC recurrence in 144 patients who underwent living donor liver transplantation. Receiver operating characteristics (ROC) analysis revealed superiority of DCP and AFP over preoperative tumor size or number for predicting recurrence. Multivariate analysis revealed tumor size >5 cm, ≥11 nodules, and DCP >400 mAU/mL as significant independent risk factors for recurrence. Incidence of microvascular invasion (62% vs. 27%, p = 0.0003) and poor differentiation (38% vs. 16%, p = 0.0087) were significantly higher for patients with DCP >400 mAU/mL than for patients with DCP ≤400 mAU/mL. In ROC analysis for patients with ≤10 nodules all ≤5 cm to predict recurrence, area under the curve was much higher for DCP than for AFP (0.84 vs. 0.69). Kyoto criteria were thus defined as ≤10 nodules all ≤5 cm, and DCP ≤400 mAU/mL. The 5-year recurrence rate for 28 patients beyond-Milan but within-Kyoto criteria was as excellent as that for 78 patients within-Milan criteria (3% vs. 7%). The preoperative DCP level offers additional information regarding histological features, and thus can greatly improve patient selection criteria when used with tumor bulk information.

show abstract

Study on Time Course of PIVKA-II and AFP levels after hepatic artery embolization for hepatocellular carcinomas. Relation between time course in PIVKA-II and AFP levels and tumor necrosis.

Cited by 10 publications

References 0 publications

Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma

Evaluation methods for pretransplant oncologic markers and their prognostic impacts in patient undergoing living donor liver transplantation for hepatocellular carcinoma

Tumor Marker Levels Before and After Curative Treatment of Hepatocellular Carcinoma as Predictors of Patient Survival

Significance of Des-Gamma-Carboxy Prothrombin in Selection Criteria for Living Donor Liver Transplantation for Hepatocellular Carcinoma

Contact Info

Product

Resources

About